Abstract
Ischemic reperfusion (I/R) is the primary cause of acute kidney injury (AKI) in hospitalized patients. Although AKI resolution occurs in few days, it predisposes kidneys to progressive renal injury. Previously, administration of rennin-angiotensin-aldosterone system (RAAS) blocker spironolactone in acute phase was reported to attenuate various manifestations of chronic kidney disease (CKD) in rats. The present study investigates the effects of RAAS blockade during progressive kidney disease (30 days onwards) on CKD outcomes in rodent model of I/R injury. CKD was induced by clamping both renal pedicles for 45 min followed by 90 days of reperfusion in rats. Single and dual RAAS blocker therapy was initiated at 30 days post-I/R injury and continued until the end of the study period. Evaluation of proteinuria and creatinine levels was done every 30 days in various study groups. Assessment of CKD was done by analyzing renal tissue oxidative stress, inflammatory biomarker levels, and histological changes after 90 days of I/R injury. After 90 days, I/R rat kidneys displayed hypertrophy, reduced body weight, increased oxidative stress, elevated inflammatory biomarker levels, and histological abnormalities such as glomerulosclerosis, mesangial expansion, and tubulointerstitial fibrosis. Treatment with losartan or spironolactone alone significantly reduced various CKD-associated features. Remarkably, combined treatment with dual RAAS blocker in low dose or high dose exhibited highest beneficial effects on various parameters in CKD model, with low-dose combination showing fewer side effects. Therefore, we propose that combined low-dose RAAS blockade therapy might serve as a better therapeutic approach for retarding progressive kidney disease transition to CKD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aebi H (1974) Catalase. In: Methods of enzymatic analysis. Elsevier, pp 673–684
Barrera-Chimal J, Pérez-Villalva R, Rodríguez-Romo R, Reyna J, Uribe N, Gamba G, Bobadilla NA (2013) Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury. Kidney Int 83:93–103. https://doi.org/10.1038/ki.2012.352
Barrera-Chimal J, Rocha L, Amador-Martínez I et al (2019) Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation. Nephrol Dial Transplant 34:794–801. https://doi.org/10.1093/ndt/gfy246
Basile DP, Donohoe D, Roethe K, Osborn JL (2001) Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol-Ren Physiol 281:F887–F899. https://doi.org/10.1152/ajprenal.00050.2001
Basile DP, Leonard EC, Beal AG et al (2012) Persistent oxidative stress following renal ischemia-reperfusion injury increases ANG II hemodynamic and fibrotic activity. Am J Physiol-Ren Physiol 302:F1494–F1502. https://doi.org/10.1152/ajprenal.00691.2011
Bedford M, Farmer C, Levin A, Ali T, Stevens P (2012) Acute kidney injury and CKD: chicken or egg? Am J Kidney Dis 59:485–491. https://doi.org/10.1053/j.ajkd.2011.09.010
Bomback AS, Kshirsagar AV, Amamoo MA et al (2008) Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 51:199–211
Boyne AF, Ellman GL (1972) A methodology for analysis of tissue sulfhydryl components. Anal Biochem 46:639–653. https://doi.org/10.1016/0003-2697(72)90335-1
Chawla LS, Kimmel PL (2012) Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int 82:516–524
Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Cabrini G, Bonizzato A, Graziani M, Anker SD, Coats AJ, Zardini P (2001) Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 37:1808–1812
Coca SG, Singanamala S, Parikh CR (2012) Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 81:442–448
Conger JD, Robinette JB, Hammond WS (1991) Differences in vascular reactivity in models of ischemic acute renal failure. Kidney Int 39:1087–1097. https://doi.org/10.1038/ki.1991.138
Donnahoo KK, Meng X, Ayala A et al (1999) Early kidney TNF-α expression mediates neutrophil infiltration and injury after renal ischemia-reperfusion. Am J Physiol-RegulIntegr Comp Physiol 277:R922–R929. https://doi.org/10.1152/ajpregu.1999.277.3.R922
Glynne PA, Picot J, Evans TJ (2001) Co expressed nitric oxide synthase and apical beta(1) integrins influence tubule cell adhesion after cytokine-induced injury. J Am Soc Nephrol 12(11):2370–2383
Hirst JA, Taylor KS, Stevens RJ et al (2012) The impact of renin–angiotensin–aldosterone system inhibitors on Type 1 and Type 2 diabetic patients with and without early diabetic nephropathy. Kidney Int 81:674–683
Hirose R, Xu F, Dang K, Liu T, Behrends M, Brakeman PR, Wiener-Kronish J, Niemann CU (2008) Transient hyperglycemia affects the extent of ischemia-reperfusion-induced renal injury in rats. Anaesthesiology 108(3):402–414
Ivanov M, Mihailović-Stanojević N, Grujić Milanović J et al (2014) Losartan improved antioxidant defense, renal Function and structure of Postischemic Hypertensive Kidney. PLoS ONE 9:e96353. https://doi.org/10.1371/journal.pone.0096353
Jefferson JA, Shankland SJ, Pichler RH (2008) Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 74:22–36. https://doi.org/10.1038/ki.2008.128
Junge W, Wilke B, Halabi A, Klein G (2004) Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffé method. Clin Chim Acta 344:137–148. https://doi.org/10.1016/j.cccn.2004.02.007
Kang YS, Ko GJ, Lee MH et al (2008) Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats. Nephrol Dial Transplant 24:73–84. https://doi.org/10.1093/ndt/gfn448
Lee MY, Shim MS, Kim BH et al (2011) Effects of spironolactone and losartan on diabetic nephropathy in a type 2 diabetic rat model. Diabetes Metab J 35:130. https://doi.org/10.4093/dmj.2011.35.2.130
Lozano-Maneiro L, Puente-García A (2015) Renin-angiotensin-aldosterone system blockade in diabetic nephropathy. Present Evidences J Clin Med 4:1908–1937. https://doi.org/10.3390/jcm4111908
Malek M (2015) Renal ischemia/reperfusion injury; from pathophysiology to treatment. J Renal. Inj Prev. https://doi.org/10.12861/jrip.2015.06
Medeiros M, Velásquez-Jones L, Hernández AM, Ramón-García G, Valverde S, Fuentes Y, Vargas A, Patiño M, Pérez-Villalva R, Ortega-Trejo JA, Barrera-Chimal J, Bobadilla NA (2017) Randomized controlled trial of mineralocorticoid receptor blockade in children with chronic kidney allograft nephropathy. Clin J Am Soc Nephrol 12:1291–1300. https://doi.org/10.2215/CJN.05300516
Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358. https://doi.org/10.1016/0003-2697(79)90738-3
Rachmani R, Slavachevsky I, Amit M et al (2004) The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 21(5):471–475
Ritz E (2003) Angiotensin II and oxidative stress: an unholy alliance. J Am Soc Nephrol 14:2985–2987. https://doi.org/10.1097/01.ASN.0000096784.86791.21
Rodríguez-Romo R, Benítez K, Barrera-Chimal J, Pérez-Villalva R, Gómez A, Aguilar-León D, Rangel-Santiago JF, Huerta S, Gamba G, Uribe N, Bobadilla NA (2016) AT1 receptor antagonism before ischemia prevents the transition of acute kidney injury to chronic kidney disease. Kidney Int 89:363–373. https://doi.org/10.1038/ki.2015.320
Rüster C, Wolf G (2006) Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 17:2985–2991. https://doi.org/10.1681/ASN.2006040356
Sato A, Saruta T (2001) Aldosterone escape during angiotensin converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 29:13–21. https://doi.org/10.1177/147323000102900103
Savory J, Pu PH, Sunderman FW (1968) A biuret method for determination of protein in normal urine. Clin Chem 14(12):1160–1171
Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH (2004) Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47(11):1936–1939
Singh G, Krishan P (2018) Cobalt treatment does not prevent glomerular morphological alterations in type 1 diabetic rats. Naunyn Schmiedebergs Arch Pharmacol 391:933–944. https://doi.org/10.1007/s00210-018-1511-7
Staessen J, Lijnen P, Fagard R (1981) Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91(3):457–465
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interests
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving animals were in accordance with the ethical standards of the ISF College of Pharmacy, Moga, Punjab, India (ISFCP/IAEC/CPCSEA/Meeting No. 23/2018/Protocol No. 371).
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Aggarwal, D., Singh, G. Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats. Naunyn-Schmiedeberg's Arch Pharmacol 393, 615–627 (2020). https://doi.org/10.1007/s00210-019-01759-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-019-01759-3